Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major economic data or central-bank announcements released this hour.
  • No significant geopolitical or security events reported this hour.
  • Equity and bond markets saw limited movement due to lack of newsflow.
  • Commodity and FX markets traded in narrow ranges without fresh drivers.
  • Political calendars showed no breaking developments or legislative actions in the past hour.

Latest Articles

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Oct 5, 2026
Derek Hwang
Press Releases

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Crescent Biopharma announced FDA clearance of the IND application for CR-002, a topoisomerase inhibitor antibody-drug conjugate targeting PD-L1, intended to treat advanced solid tumors. The company plans to launch the global Phase 1/2 APOLLO trial in Q4 2026, enrolling approximately 200 patients with various solid tumors such as NSCLC and HNSCC, wi…

CBIO
Nexus Advanced Technologies Announces Anson Note and Warrant Restructuring Agreement with Anson Funds
Oct 5, 2026
Caleb Monroe
Press Releases

Nexus Advanced Technologies Announces Anson Note and Warrant Restructuring Agreement with Anson Funds

Nexus Advanced Technologies Inc. announced an agreement with Anson Funds to restructure convertible notes and warrants. This agreement aims to simplify the company's capital structure by fixing conversion prices, eliminating anti-dilution provisions, and enabling a warrant exchange that will dilute existing shareholders but retire adjustment provis…

NXAT
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
Oct 5, 2026
Leila Farooq
Press Releases

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

BridgeBio Pharma announced new 12-month interim data from its Phase 3 FORTIFY trial demonstrating that BBP-418, an oral therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), significantly improves cardiac biomarkers such as high-sensitivity troponin I and left ventricular ejection fraction. The therapy increased glycosylated alpha-dyst…

BBIO
Buying the Safety Net: A 45-Day Swing Trade on Strategy Inc. (MSTR)
Oct 5, 2026
Ajmal Hussain
Trade Ideas

Buying the Safety Net: A 45-Day Swing Trade on Strategy Inc. (MSTR)

Strategy Inc. (MSTR) is trading as a levered play on Bitcoin but with a now-visible liquidity cushion: current assets of roughly $6.05B and cash of $5.59B. That buffer, plus signs management will manage the balance sheet after selling up to $1.25B of BTC, creates a tactical swing opportunity to buy exposure at $162 with a $220 target over the next …

MSTR
Jiuzi Holdings’ AI Smart Imaging Platform Accelerates Toward Completion: Enterprise-Grade Solution Nears Commercialization; Million-Dollar Profit Expectation Opens New Growth Space
Oct 5, 2026
Sofia Navarro
Press Releases

Jiuzi Holdings’ AI Smart Imaging Platform Accelerates Toward Completion: Enterprise-Grade Solution Nears Commercialization; Million-Dollar Profit Expectation Opens New Growth Space

Jiuzi Holdings, Inc. (NASDAQ: JZXN) announced significant progress on its AI smart imaging and data platform, evolving it into an enterprise-grade, modular, and scalable solution targeting smart retail, intelligent security, media content management, and advanced driver assistance applications. The company anticipates approximately $1.55 million in…

JZXN
Gilat Awarded $28 Million Contract to Expand Connectivity in Peru
Oct 5, 2026
Avery Klein
Press Releases

Gilat Awarded $28 Million Contract to Expand Connectivity in Peru

Gilat Satellite Networks Ltd. announced a $28 million contract awarded to its Peruvian subsidiary to enhance broadband connectivity in the Ica region of Peru. The project includes network upgrades that will deliver internet speeds 20 times faster to public institutions and expand free Wi-Fi access to public squares, with construction to be complete…

GILT
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Oct 5, 2026
Hana Yamamoto
Press Releases

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

Alterity Therapeutics presented additional analyses from its Phase 2 trial of ATH434 in Multiple System Atrophy (MSA), demonstrating that the 50 mg dose significantly slowed functional decline by approximately 52% compared to placebo at 52 weeks when adjusted for baseline disease severity using CSF neurofilament light chain (NfL). The findings supp…

ATHE
VisionWave Outlines Development of Autonomous Defense Ecosystem Across Tactical UAV and Counter-UAS Applications
Oct 5, 2026
Jordan Park
Press Releases

VisionWave Outlines Development of Autonomous Defense Ecosystem Across Tactical UAV and Counter-UAS Applications

VisionWave Holdings, Inc. outlines the development of its integrated autonomous defense ecosystem, featuring a range of tactical UAVs for ISR, logistics, strike, and counter-UAS applications. None of the platforms are currently in production or have customer orders. The company is actively pursuing U.S. and international counter-UAS contracts but h…

VWAV
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
Oct 5, 2026
Avery Klein
Press Releases

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BioCryst Pharmaceuticals has established a Scientific Advisory Board composed of experts in rare disease research and drug development to guide its R&D strategy and pipeline growth. This move supports the company's transition to an innovation-driven R&D model focusing on external partnerships and advancing therapies for rare diseases, including her…

BCRX
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Oct 5, 2026
Ajmal Hussain
Press Releases

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Alector has entered an exclusive licensing agreement with Genentech, granting worldwide rights to develop and commercialize its AL050 brain-penetrant GCase enzyme replacement therapy targeting Parkinson's disease and other neurodegenerative conditions. The deal includes a $100 million upfront payment, potential milestones totaling $1.17 billion, an…

ALEC
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Oct 5, 2026
Avery Klein
Press Releases

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Psyence Biomedical Ltd., via its Texas subsidiary Texas Ibogaine Research Corporation (TIRC), has partnered with Benuvia Operations, a DEA-registered controlled substance manufacturer in Texas, to establish U.S. manufacturing of pharmaceutical-grade ibogaine active pharmaceutical ingredient (API). This partnership aims to integrate Psyence BioMed’s…

PBM
Harrow Closes Acquisition of TYRVAYA®
Oct 5, 2026
Maya Rios
Press Releases

Harrow Closes Acquisition of TYRVAYA®

Harrow, Inc. announced the closing of its acquisition of TYRVAYA (varenicline solution) nasal spray from Viatris, securing global rights except for Japan. TYRVAYA is the first FDA-approved nasal spray for dry eye disease (DED) and complements Harrow's existing DED therapy, VEVYE. The acquisition expands Harrow's commercial footprint in the growing …

HROW
TurboGen Announces New Agreement with Leading Engineering and Manufacturing Company for Serial Development and Manufacturing of Its 20kW Systems for the Defense and Civilian Markets
Oct 5, 2026
Nina Shah
Press Releases

TurboGen Announces New Agreement with Leading Engineering and Manufacturing Company for Serial Development and Manufacturing of Its 20kW Systems for the Defense and Civilian Markets

TurboGen Ltd. announces a multi-year agreement with a top-tier European engineering and manufacturing company to transition from prototype to serial production of its 20kW combined heat and power microturbine systems, targeting both defense and civilian markets. This partnership aims to facilitate commercialization, enhance revenue streams, and exp…

TRBG
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Oct 5, 2026
Jordan Park
Press Releases

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Rezolute, Inc. announced that the FDA has recommended a pre-BLA meeting following review of Phase 3 sunRIZE study data for ersodetug, a treatment candidate for congenital hyperinsulinism. Although sunRIZE did not meet its primary endpoint, consistent clinical improvements were observed, prompting the agency to encourage further evaluation through a…

RZLT
Satellos Granted Composition of Matter Patent for Forazapadin
Oct 5, 2026
Ajmal Hussain
Press Releases

Satellos Granted Composition of Matter Patent for Forazapadin

Satellos Bioscience Inc., a clinical-stage drug developer focused on degenerative muscle diseases, has been granted a U.S. composition of matter patent for forazapadin, its lead clinical-stage drug candidate targeting AAK1 inhibition to promote muscle regeneration. The patent offers protection through September 2044 with potential extension after F…

MSLE
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Oct 5, 2026
Hana Yamamoto
Press Releases

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics and Gilead Sciences have agreed to a second two-year extension of their research collaboration on an undisclosed oncology program, underscoring the productive partnership initiated in 2019. Nurix retains co-development and profit-sharing options for up to two programs in the U.S., and will receive a $10 million extension fee. The…

NRIX
Wabash Schedules Third Quarter 2026 Earnings Conference Call
Oct 5, 2026
Leila Farooq
Press Releases

Wabash Schedules Third Quarter 2026 Earnings Conference Call

Wabash National Corporation (NYSE: WNC) has scheduled its third quarter 2026 earnings conference call for October 29, 2026, at 12:00 p.m. ET. The call will be webcast and accompanied by a slide presentation accessible in the investors section of the company's website. Financial results, along with presentation materials, will be posted prior to the…

WNC